Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251107/
https://www.ncbi.nlm.nih.gov/pubmed/32238921
http://dx.doi.org/10.1038/s41416-020-0802-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251107/
https://www.ncbi.nlm.nih.gov/pubmed/32238921
http://dx.doi.org/10.1038/s41416-020-0802-1

Ejemplares similares